Concepedia

Ai Li

AL

Statistics

Publications

8

Citations

325

H-Index

8

Active since

2005

Affiliations

Memorial Sloan Kettering Cancer Center(Current)

QED Technologies (United States)

The University of Texas MD Anderson Cancer Center

Massachusetts General Hospital

Vall d'Hebron Hospital Universitari

Ai Li is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, oncology, and pharmacology.

ORCID

Publications per year

2005–2022

8

Publications

8

Infigratinib in patients with advanced cholangiocarcinoma with <i>FGFR2</i> gene fusions/translocations: the PROOF 301 trial

Shalini Makawita, Ghassan K. Abou‐Alfa, Sameek Roychowdhury et al. · Future Oncology · 2020 · 91 citations · Full text

, , +17

Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an <i>FGFR2</i> gene fusion or rearrangement.

Milind Javle, Sameek Roychowdhury, Robin Kate Kelley et al. · Journal of Clinical Oncology · 2021 · 86 citations

, , +17

Identification and determination of nucleosides in Cordyceps sinensis and its substitutes by high performance liquid chromatography with mass spectrometric detection

Fang-Qiu Guo, Ai Li, Lan‐Fang Huang et al. · Journal of Pharmaceutical and Biomedical Analysis · 2005 · 61 citations

, , +15

Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1–3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3–altered Advanced/Metastatic Urothelial Carcinoma

Yung Lyou, Petros Grivas, Jonathan E. Rosenberg et al. · European Urology · 2020 · 26 citations · Full text

, , +14

Elevated MED28 expression predicts poor outcome in women with breast cancer

Nam K. Yoon, Erin L. Maresh, Yahya Elshimali et al. · BMC Cancer · 2010 · 22 citations · Full text

, , +17

1–5 of 8